Description

Human papillomavirus infection (HPV infection) is caused by a DNA virus from the Papillomaviridae family. Many HPV infections cause no symptoms and 90% resolve spontaneously within two years. Available HPV vaccines protect against either two, four, or nine types of HPV. All HPV vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers. A study by StrategyHelix indicates that the global human papillomavirus market is expected to increase by US$ 2.5 billion from 2022 to 2028, garnering a CAGR of 6.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for human papillomavirus. The global human papillomavirus market is segmented on the basis of type, dosage, application, age, end user, and region. Based on type, the global human papillomavirus market is categorized into bivalent HPV vaccine (2vHPV), quadrivalent HPV vaccine (4vHPV), 9-valent HPV vaccine (9vHPV). On the basis of dosage, the global human papillomavirus market has been segmented into 2 dose, 3 dose. By application, the global human papillomavirus market has been segmented into HPV-attributable cancer, genital warts. Based upon age, the global human papillomavirus market is categorized into under 15 years, 15 to 45 years. On the basis of end user, the global human papillomavirus market has been segmented into community clinics, doctor’s office, health departments, hospitals, school-based health centers, others. In terms of geography, the global human papillomavirus market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global human papillomavirus market is highly competitive. The key players in the human papillomavirus market include Beijing Health Guard Biotechnology Inc., Beijing Wantai Biopharmaceutical Co. Ltd., BioLeaders Corporation, GSK plc, Inovio Pharmaceuticals Inc., Merck & Co. Inc., R-Pharm Group, Sanofi S.A., Serum Institute of India Pvt. Ltd., Vaccitech plc, Walvax Biotechnology Co. Ltd. Competitive landscape gives a description of the competitive nature of the global human papillomavirus market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the human papillomavirus market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: bivalent HPV vaccine (2vHPV), quadrivalent HPV vaccine (4vHPV), 9-valent HPV vaccine (9vHPV)
Dosage: 2 dose, 3 dose
Application: HPV-attributable cancer, genital warts
Age: under 15 years, 15 to 45 years
End user: community clinics, doctor’s office, health departments, hospitals, school-based health centers, others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: Beijing Health Guard Biotechnology Inc., Beijing Wantai Biopharmaceutical Co. Ltd., BioLeaders Corporation, GSK plc, Inovio Pharmaceuticals Inc., Merck & Co. Inc., R-Pharm Group, Sanofi S.A., Serum Institute of India Pvt. Ltd., Vaccitech plc, Walvax Biotechnology Co. Ltd.

Key Benefits for Stakeholders

– Get a comprehensive picture of the global human papillomavirus market
– Identify regional strategies and strategic priorities on the basis of local data
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Human papillomavirus market overview
Part 3. Market breakdown by type
– Bivalent HPV vaccine (2vHPV)
– Quadrivalent HPV vaccine (4vHPV)
– 9-valent HPV vaccine (9vHPV)
Part 4. Market breakdown by dosage
– 2 dose
– 3 dose
Part 5. Market breakdown by application
– HPV-attributable cancer
– Genital warts
Part 6. Market breakdown by age
– Under 15 years
– 15 to 45 years
Part 7. Market breakdown by end user
– Community clinics
– Doctor’s office
– Health departments
– Hospitals
– School-based health centers
– Others
Part 8. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 9. Key companies
– Beijing Health Guard Biotechnology Inc.
– Beijing Wantai Biopharmaceutical Co., Ltd.
– BioLeaders Corporation
– GSK plc
– Inovio Pharmaceuticals, Inc.
– Merck & Co., Inc.
– R-Pharm Group
– Sanofi S.A.
– Serum Institute of India Pvt. Ltd.
– Vaccitech plc
– Walvax Biotechnology Co., Ltd.
About StrategyHelix
Disclaimer